Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Acro Biomedical (ACBM) Gross Margin (2017 - 2022)

Acro Biomedical (ACBM) has 6 years of Gross Margin data on record, last reported at 17.78% in Q4 2022.

  • For Q4 2022, Gross Margin fell 731.0% year-over-year to 17.78%; the TTM value through Sep 2023 reached 17.78%, down 749.0%, while the annual FY2022 figure was 21.34%, 33.0% down from the prior year.
  • Gross Margin reached 17.78% in Q4 2022 per ACBM's latest filing, down from 25.63% in the prior quarter.
  • Across five years, Gross Margin topped out at 29.65% in Q1 2021 and bottomed at 1.04% in Q4 2019.
  • Average Gross Margin over 5 years is 16.15%, with a median of 16.0% recorded in 2021.
  • Peak YoY movement for Gross Margin: tumbled -1104bps in 2019, then surged 648bps in 2021.
  • A 5-year view of Gross Margin shows it stood at 10.0% in 2018, then plummeted by -110bps to 1.04% in 2019, then skyrocketed by 2323bps to 23.17% in 2020, then increased by 8bps to 25.08% in 2021, then fell by -29bps to 17.78% in 2022.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 17.78% in Q4 2022, 25.63% in Q1 2022, and 25.08% in Q4 2021.